Every 8-K that REGENEREX PHARMA INC (RGPX) has filed with the SEC in the last 24 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A 8-K covers material events a company has to report between its quarterly reports, so if you follow RGPX and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full RGPX filings page.
REGENEREX PHARMA, INC. (RGPX) reports that its independent registered public accounting firm, dbbmckennon, resigned effective August 31, 2026, after serving in that role since 2017. The board acknowledged and accepted the firm’s internal decision to cease providing services.
dbbmckennon’s reports on the company’s financial statements for the fiscal years ended March 31, 2025 and December 31, 2025 contained no adverse or disclaimed opinions and were not qualified, but did include an explanatory paragraph raising substantial doubt about the company’s ability to continue as a going concern, and for the April 1–December 31, 2025 transition period also noted a revision to disclose related party transactions. The company states there were no disagreements or reportable events with dbbmckennon under Regulation S‑K and is in the process of engaging a successor auditor while working to complete outstanding periodic reports and bring its SEC filings current.
REGENEREX PHARMA, INC. (RGPX) reports that its Annual Report on Form 10-K for the fiscal year ended December 31, 2025 has been completed and filed, but after the applicable deadline. Quarterly Reports on Form 10-Q for the quarters ended March 31, 2026 and June 30, 2026 remain unfiled and are delinquent, and the company did not submit Notifications of Late Filing on Form 12b-25 for these periods. Management describes substantial additional accounting, reconciliation, and review work undertaken to complete the 2025 Form 10-K and to prepare the outstanding quarterly financial statements, and states it is working with internal staff and external advisors to become current in SEC reporting as promptly as practicable. The company states it does not currently anticipate changes to its operations or business strategy due to the filing delays but cautions that financial information for the affected quarters is incomplete and should be evaluated together with other SEC filings.
Regenerex Pharma, Inc. placed its Chief Financial Officer, Kenneth Perry, on paid administrative suspension leave effective March 31, 2026, after the Board cited concerns about compliance with Board directives, financial oversight, corporate governance, and the company’s financial reporting processes and internal controls. The company states that these matters are under review and that no final determinations have been made. Mr. Perry remains an employee and continues to receive his base salary and benefits. Effective April 1, 2026, the Board appointed Don E. Ray as Interim Chief Financial Officer on a 90-day initial term with an interim salary of $150,000 annually, bringing extensive public-company auditing and automotive industry financial leadership experience.
Regenerex Pharma (RGPX) changed its fiscal year end to December 31. The Board approved moving the company’s fiscal year end from March 31 to December 31. To bridge the shift, the company will file a transition report on Form 10-K covering the period from April 1, 2025 through December 31, 2025.
This is an administrative change to align reporting periods. The upcoming transition 10-K will provide financials for the nine-month period noted before the new annual cycle begins on a calendar-year basis.